Deerfield Management Company, L.P.

Institutional investor · Portfolio as of Q4 2023

Q4 2023 biggest moves
  • OSCROSCR

    Oscar Health

    New

    1.9% of portfolio

  • BAXBAX

    Baxter International

    New

    1.0% of portfolio

  • RVMDRVMD

    Revolution Medicines

    Added 76%

    now 1.6% of portfolio

  • NBIXNBIX

    Neurocrine Biosciences

    Cut 26%

    now 2.2% of portfolio

208 changes in all

Top Holdings222 positions

Checking export access…
Activity:
NUVL
NUVLDelisted

NUVALENT INC

20M$1.5B27.2%——
10 qtrssince 2021-Q3
Unchanged
0
??
GLAUKOS CORPDelisted
Bond
271.5M$414.9M7.7%——
11 qtrssince 2021-Q2
Unchanged
0
VTRS

Viatris Inc.

19.9M$215.1M4.0%$11.25-14.03%
13 qtrssince 2020-Q4
Decreased
0
??
217.8M$187M3.5%——
2 qtrssince 2023-Q3
Unchanged
0
??
NATERA INCDelisted
Bond
101M$172.4M3.2%——
11 qtrssince 2021-Q2
Unchanged
0
CPRX
CPRXDelisted

CATALYST PHARMACEUTICALS INC

8.9M$149.4M2.8%——
6 qtrssince 2022-Q3
Increased
56
CNC

Centene Corporation

2M$147.8M2.7%$66.14+12.20%
17 qtrssince 2019-Q4
Increased
52
146M$133.2M2.5%——
5 qtrssince 2022-Q4
Unchanged
0
??
INSMED INCDelisted
Bond
117M$123.5M2.3%——
16 qtrssince 2020-Q1
Increased
56
NBIX

Neurocrine Biosciences, Inc.

896,719$118.2M2.2%$95.92+37.36%
12 qtrssince 2021-Q1
Decreased
0
??
ACCOLADE INCDelisted
Bond
132.6M$114M2.1%——
7 qtrssince 2022-Q2
Unchanged
0
OSCR

Oscar Health, Inc.

11.2M$102.9M1.9%$9.150.00%
1 qtr
New
68
ACH

Accendra Health, Inc.

5.2M$100.8M1.9%$16.50+16.81%
5 qtrssince 2022-Q4
Decreased
0
AHCO

AdaptHealth Corp.

13.6M$99.2M1.8%$18.05-59.60%
17 qtrssince 2019-Q4
Unchanged
0
SWTX
SWTXAcquired

SPRINGWORKS THERAPEUTICS INC

2.6M$94.3M1.7%——
6 qtrssince 2022-Q3
Increased
69
IDYA

IDEAYA Biosciences, Inc.

2.6M$93.6M1.7%$19.47+82.71%
6 qtrssince 2022-Q3
Increased
54
DCPH
DCPHDelisted

DECIPHERA PHARMACEUTICALS IN

5.8M$93.4M1.7%——
17 qtrssince 2019-Q4
Decreased
0
RVMD

Revolution Medicines, Inc.

3.1M$88.6M1.6%$26.00+10.32%
16 qtrssince 2020-Q1
Increased
71
BKD

Brookdale Senior Living Inc.

14.8M$86.1M1.6%$4.29+35.71%
17 qtrssince 2019-Q4
Increased
54
MRUS
MRUSDelisted

MERUS N V

3M$83M1.5%——
9 qtrssince 2021-Q4
Decreased
0
$5.4B
AUM
222
Positions
Q4 2023
Filing
HI rating · 1.0/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2022-Q3$5,023,740,0003.61685684355%
2022-Q4$4,831,008,337-3.83641794758%
2023-Q1$4,485,670,170-7.14836619832%
2023-Q2$4,684,196,2414.42578396262%
2023-Q3$4,538,793,245-3.10411836992%
2023-Q4$5,415,638,75919.3189129063%
Activity profile
$ moved · Q4'23
New22%Increased31%Decreased10%Exited37%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 3.5 quarters
<1Q63%1-4Q8%1-2Y0%2Y+29%

Deerfield Management Company, L.P. manages $5.4B across 222 positions as of Q4 2023. Top holdings: NUVL (27.2%), GLAUKOS CORP (7.7%), VTRS (4.0%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 1/5.0.

Top holdings by portfolio weight

Total AUM$5B
NUVL27.16%
GLAUKOS CORP7.66%
VTRS3.97%
Invitae Corp3.45%
NATERA INC3.18%
CPRX2.76%
CNC2.73%
BROOKDALE SR2.46%
INSMED INC2.28%
NBIX2.18%
Other2.11%

Portfolio allocation by GICS sector

Sectors11
Healthcare90.11%
Unknown9.23%
Technology0.11%
Industrials0.11%
Consumer Cyclical0.11%
Financial Services0.08%
Consumer Defensive0.08%
Basic Materials0.06%
Energy0.04%
Communication Services0.04%
Other0.04%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Weak(1.0 / 5.0)
Holdings P&L32
Conviction55
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
5Q
BCRXBCRXBioCryst Pharmaceuticals, Inc.
Q3 2025 → Q3 2026+10.8M shares+$87M
3Q
TNGXTNGXTango Therapeutics, Inc.
Q1 2026 → Q3 2026+2.3M shares+$103.5M
2Q
BMRNBMRNBioMarin Pharmaceutical Inc.
Q2 2026 → Q3 2026+1.2M shares+$73.4M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used